BRCA1 and prostate carcinoma: BRCA1/2-deficient prostate cancers not only show increased sensitivity to platinum-based chemotherapies [11], but also to poly-(ADP-ribose) polymerase (PARP) inhibitors [12–14], thus giving BRCA1/2 deficiency a high clinical relevance in these patients [15, 16].